Prognostic utility and characteristics of MIB-1 labeling index as a proliferative activity marker in childhood low-grade glioma: a retrospective observational study.
KI-67
Low-grade glioma
MIB-1
Proliferation index
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
received:
26
07
2023
accepted:
13
03
2024
medline:
6
4
2024
pubmed:
6
4
2024
entrez:
5
4
2024
Statut:
epublish
Résumé
The prognostic utility of MIB-1 labeling index (LI) in pediatric low-grade glioma (PLGG) has not yet conclusively been described. We assess the correlation of MIB-1 LI and tumor growth velocity (TGV), aiming to contribute to the understanding of clinical implications and the predictive value of MIB-1 LI as an indicator of proliferative activity and progression-free survival (PFS) in PLGG. MIB-1 LI of a cohort of 172 nonependymal PLGGs were comprehensively characterized. Correlation to TGV, assessed by sequential MRI-based three-dimensional volumetry, and PFS was analyzed. Mean MIB-1 LI accounted for 2.7% (range: < 1-10) and showed a significant decrease to 1.5% at secondary surgery (p = .0013). A significant difference of MIB-1 LI in different histopathological types and a correlation to tumor volume at diagnosis could be shown. Linear regression analysis showed a correlation between MIB-1 LI and preoperative TGV (R These data confirm a correlation of MIB-1 LI and radiologically detectable TGV in PLGG for the first time. Compared with preoperative TGV, a crucially decreasing correlation of MIB-1 LI and TGV after surgery may result in limited prognostic capability of MIB-1 LI in PLGG.
Identifiants
pubmed: 38580878
doi: 10.1007/s00432-024-05701-w
pii: 10.1007/s00432-024-05701-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Informations de copyright
© 2024. The Author(s).
Références
Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ (2009) Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 101(13):946–958. https://doi.org/10.1093/jnci/djp148
doi: 10.1093/jnci/djp148
pubmed: 19535780
pmcid: 2704230
Avinash KS, Thakar S, Aryan S, Ghosal N, Hegde AS (2019) Malignant transformation of pediatric low-grade gliomas: report of two cases and review of a rare pathological phenomenon. Neurol India 67(4):1100–1106. https://doi.org/10.4103/0028-3886.266259
doi: 10.4103/0028-3886.266259
pubmed: 31512645
Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, Guo D, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley PE (2014) Long-term outcome of 4040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61(7):1173–1179. https://doi.org/10.1002/pbc.24958
doi: 10.1002/pbc.24958
pubmed: 24482038
pmcid: 4657506
Benesch M, Eder HG, Sovinz P, Raith J, Lackner H, Moser A, Urban C (2006) Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003. Pediatr Neurosurg 42(3):159–164. https://doi.org/10.1159/000091859
doi: 10.1159/000091859
pubmed: 16636617
Bowers DC, Mulne AF, Weprin B, Bruce DA, Shapiro K, Margraf LR (2002) Prognostic factors in children and adolescents with low-grade oligodendrogliomas. Pediatr Neurosurg 37(2):57–63. https://doi.org/10.1159/000065106
doi: 10.1159/000065106
pubmed: 12145513
Bowers DC, Gargan L, Kapur P, Reisch JS, Mulne AF, Shapiro KN, Elterman RD, Winick NJ, Margraf LR (2003) Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol 21(15):2968–2973. https://doi.org/10.1200/JCO.2003.01.017
doi: 10.1200/JCO.2003.01.017
pubmed: 12885817
Chamdine O, Broniscer A, Wu S, Gajjar A, Qaddoumi I (2016) Metastatic low-grade gliomas in children: 20 years’ experience at St. Jude children’s research hospital. Pediatr Blood Cancer 63(1):62–70. https://doi.org/10.1002/pbc.25731
doi: 10.1002/pbc.25731
pubmed: 26312767
Cherlow JM, Shaw DWW, Margraf LR, Bowers DC, Huang J, Fouladi M, Onar-Thomas A, Zhou T, Pollack IF, Gajjar A, Kessel SK, Cullen PL, McMullen K, Wellons JC, Merchant TE (2019) Conformal radiation therapy for pediatric patients with low-grade glioma: results from the children’s oncology group phase 2 study ACNS0221. Int J Radiat Oncol Biol Phys 103(4):861–868. https://doi.org/10.1016/j.ijrobp.2018.11.004
doi: 10.1016/j.ijrobp.2018.11.004
pubmed: 30419305
Cler SJ, Skidmore A, Yahanda AT, Mackey K, Rubin JB, Cluster A, Perkins S, Gauvain K, King AA, Limbrick DD, McEvoy S, Park TS, Smyth MD, Mian AY, Chicoine MR, Dahiya S, Strahle JM (2022) Genetic and histopathological associations with outcome in pediatric pilocytic astrocytoma. J Neurosurg Pediatr 29(5):504–512. https://doi.org/10.3171/2021.9.PEDS21405
doi: 10.3171/2021.9.PEDS21405
pubmed: 35148515
Dorward IG, Luo J, Perry A, Gutmann DH, Mansur DB, Rubin JB, Leonard JR (2010) Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr 6(4):346–352. https://doi.org/10.3171/2010.7.PEDS10129
doi: 10.3171/2010.7.PEDS10129
pubmed: 20887107
Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L (2001) Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys 51(3):704–710. https://doi.org/10.1016/s0360-3016(01)01705-9
doi: 10.1016/s0360-3016(01)01705-9
pubmed: 11597812
Fisher BJ, Naumova E, Leighton CC, Naumov GN, Kerklviet N, Fortin D, Macdonald DR, Cairncross JG, Bauman GS, Stitt L (2002) Ki-67: a prognostic factor for low-grade glioma? Int J Radiat Oncol Biol Phys 52(4):996–1001. https://doi.org/10.1016/s0360-3016(01)02720-1
doi: 10.1016/s0360-3016(01)02720-1
pubmed: 11958894
Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20. https://doi.org/10.1002/ijc.2910310104
doi: 10.1002/ijc.2910310104
pubmed: 6339421
Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, Warmuth-Metz M, Driever PH, Soerensen N, Kortmann RD, Pietsch T, Faldum A (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German speaking society of pediatric oncology and hematology. Neuro Oncol 14(10):1265–1284. https://doi.org/10.1093/neuonc/nos202
doi: 10.1093/neuonc/nos202
pubmed: 22942186
pmcid: 3452343
Gnekow AK, Kandels D, Tilburg CV, Azizi AA, Opocher E, Stokland T, Driever PH, Schouten-van Meeteren AYN, Thomale UW, Schuhmann MU, Czech T, Goodden JR, Warmuth-Metz M, Bison B, Avula S, Kortmann RD, Timmermann B, Pietsch T, Witt O (2019) SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr. 231(3):107–135. https://doi.org/10.1055/a-0889-8256
doi: 10.1055/a-0889-8256
pubmed: 31108561
Gorodezki D, Zipfel J, Queudeville M, Sosa J, Holzer U, Kern J, Bevot A, Schittenhelm J, Nägele T, Ebinger M, Schuhmann MU (2022) Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis. J Neurooncol 160(3):567–576. https://doi.org/10.1007/s11060-022-04176-4
doi: 10.1007/s11060-022-04176-4
pubmed: 36319795
pmcid: 9758245
Greuter L, Guzman R, Soleman J (2021) Pediatric and Adult Low-Grade Gliomas: Where Do the Differences Lie? Children (basel) 8(11):1075. https://doi.org/10.3390/children8111075
doi: 10.3390/children8111075
pubmed: 34828788
Grzybicki DM, Liu Y, Moore SA, Brown HG, Silverman JF, D’Amico F, Raab SS (2001) Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 92(10):2720–2726. https://doi.org/10.1002/1097-0142(20011115)92:10%3c2720::aid-cncr1626%3e3.0.co;2-z
doi: 10.1002/1097-0142(20011115)92:10<2720::aid-cncr1626>3.0.co;2-z
pubmed: 11745208
Harris GJ, Plotkin SR, Maccollin M, Bhat S, Urban T, Lev MH, Slattery WH (2008) Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 62(6):1314–1320. https://doi.org/10.1227/01.neu.0000333303.79931.83
doi: 10.1227/01.neu.0000333303.79931.83
pubmed: 18824998
Ho DM, Wong TT, Hsu CY, Ting LT, Chiang H. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases (1998) Cancer 82(12):2459–2466. https://doi.org/10.1002/(sici)1097-0142(19980615)82:12<2459::aid-cncr21>3.0.co;2-n
Horbinski C, Hamilton RL, Lovell C, Burnham J, Pollack IF (2010) Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas. Brain Pathol 20(3):581–588. https://doi.org/10.1111/j.1750-3639.2009.00336.x
doi: 10.1111/j.1750-3639.2009.00336.x
pubmed: 19832838
Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET (1997) Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 56(8):857–865. https://doi.org/10.1097/00005072-199708000-00003
doi: 10.1097/00005072-199708000-00003
pubmed: 9258255
Hsu CY, Ho DM, Yang CF, Chiang H (2003) Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol 16(9):951–957. https://doi.org/10.1097/01.MP.0000084631.64279.BC
doi: 10.1097/01.MP.0000084631.64279.BC
pubmed: 13679460
Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ (2018) Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol 20(2):160–173. https://doi.org/10.1093/neuonc/nox141
doi: 10.1093/neuonc/nox141
pubmed: 29016845
Kałuza J, Adamek D, Pyrich M (1997) Ki-67 as a marker of proliferation activity in tumor progression of recurrent gliomas of supratentorial localization. Immunocytochem Quantit Stud Pol J Pathol 48(1):31–36
Krishnan SS, Muthiah S, Rao S, Salem SS, Madabhushi VC, Mahadevan A (2019) Mindbomb homolog-1 index in the prognosis of high-grade glioma and its clinicopathological correlation. J Neurosci Rural Pract 10(2):185–193. https://doi.org/10.4103/jnrp.jnrp_374_18
doi: 10.4103/jnrp.jnrp_374_18
pubmed: 31001003
pmcid: 6454943
Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, Ramaswamy V, Bartels U, Huang A, Laperriere N, Dirks P, Nathan PC, Greenberg M, Malkin D, Hawkins C, Bandopadhayay P, Kieran MW, Manley PE, Bouffet E, Tabori U (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 122(8):1261–1269. https://doi.org/10.1002/cncr.29907
doi: 10.1002/cncr.29907
pubmed: 26970559
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Margraf LR, Gargan L, Butt Y, Raghunathan N, Bowers DC (2011) Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas–an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol 13(7):767–774. https://doi.org/10.1093/neuonc/nor041
doi: 10.1093/neuonc/nor041
pubmed: 21653594
pmcid: 3129272
Matsumoto T, Fujii T, Yabe M, Oka K, Hoshi T, Sato K (1998) MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Histopathology 33(5):446–452. https://doi.org/10.1046/j.1365-2559.1998.00503.x
doi: 10.1046/j.1365-2559.1998.00503.x
pubmed: 9839169
McCormick D, Chong H, Hobbs C, Datta C, Hall PA (1993) Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 22(4):355–360. https://doi.org/10.1111/j.1365-2559.1993.tb00135.x
doi: 10.1111/j.1365-2559.1993.tb00135.x
pubmed: 8514278
Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME (1997) Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer 79(4):849–856
doi: 10.1002/(SICI)1097-0142(19970215)79:4<849::AID-CNCR23>3.0.CO;2-Z
pubmed: 9024724
Pollack IF, Hamilton RL, Burnham J, Holmes EJ, Finkelstein SD, Sposto R, Yates AJ, Boyett JM, Finlay JL (2002) Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery 50(6):1238–1245. https://doi.org/10.1097/00006123-200206000-00011
doi: 10.1097/00006123-200206000-00011
pubmed: 12015841
Rickert CH, Paulus W (2001) Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 17(9):503–511. https://doi.org/10.1007/s003810100496
doi: 10.1007/s003810100496
pubmed: 11585322
Ryall S, Tabori U, Hawkins C (2020a) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8(1):30. https://doi.org/10.1186/s40478-020-00902-z
doi: 10.1186/s40478-020-00902-z
pubmed: 32164789
pmcid: 7066826
Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme W, Qaddoumi I, Surrey LF, Li MM, Waanders AJ, Gilheeney S, Rosenblum M, Bale T, Tsang DS, Laperriere N, Kulkarni A, Ibrahim GM, Drake J, Dirks P, Taylor MD, Rutka JT, Laughlin S, Shroff M, Shago M, Hazrati LN, D’Arcy C, Ramaswamy V, Bartels U, Huang A, Bouffet E, Karajannis MA, Santi M, Ellison DW, Tabori U, Hawkins C (2020b) Integrated molecular and clinical analysis of 1000 pediatric low-grade gliomas. Cancer Cell 37(4):569-583.e5. https://doi.org/10.1016/j.ccell.2020.03.011
doi: 10.1016/j.ccell.2020.03.011
pubmed: 32289278
pmcid: 7169997
Sadighi ZS, Curtis E, Zabrowksi J, Billups C, Gajjar A, Khan R, Qaddoumi I (2018) Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. Pediatr Blood Cancer 65(8):e27063. https://doi.org/10.1002/pbc.27063
doi: 10.1002/pbc.27063
pubmed: 29741274
pmcid: 6310055
Schröder R, Bien K, Kott R, Meyers I, Vössing R (1991) The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol 82(5):389–394. https://doi.org/10.1007/BF00296550
doi: 10.1007/BF00296550
pubmed: 1767633
Shaw EG, Wisoff JH (2003) Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol 5(3):153–160. https://doi.org/10.1215/S1152851702000601
doi: 10.1215/S1152851702000601
pubmed: 12816721
pmcid: 1920689
Sievert AJ, Fisher MJ (2009) Pediatric low-grade gliomas. J Child Neurol 24(11):1397–1408. https://doi.org/10.1177/0883073809342005
doi: 10.1177/0883073809342005
pubmed: 19841428
pmcid: 2917804
Skjulsvik AJ, Mørk JN, Torp MO, Torp SH (2014) Ki-67/MIB-1 immunostaining in a cohort of human gliomas. Int J Clin Exp Pathol 7(12):8905–8910
pubmed: 25674263
pmcid: 4313958
Stokland T, Liu JF, Ironside JW, Ellison DW, Taylor R, Robinson KJ, Picton SV, Walker DA (2010) A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol 12(12):1257–1268. https://doi.org/10.1093/neuonc/noq092
doi: 10.1093/neuonc/noq092
pubmed: 20861086
pmcid: 3018938
Thotakura M, Tirumalasetti N, Krishna R (2014) Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Cancer Res Ther 10(3):641–645. https://doi.org/10.4103/0973-1482.139154
doi: 10.4103/0973-1482.139154
pubmed: 25313753
Tu A, Robison A, Melamed E, Buchanan I, Hariri O, Babu H, Szymanski L, Krieger M (2018) Proliferative index in pediatric pilocytic astrocytoma by region of origin and prediction of clinical behavior. Pediatr Neurosurg 53(6):395–400. https://doi.org/10.1159/000490466
doi: 10.1159/000490466
pubmed: 30428478
van Iersel L, van Santen HM, Potter B, Li Z, Conklin HM, Zhang H, Chemaitilly W, Merchant TE (2020) Clinical impact of hypothalamic-pituitary disorders after conformal radiation therapy for pediatric low-grade glioma or ependymoma. Pediatr Blood Cancer 67(12):e28723. https://doi.org/10.1002/pbc.28723
doi: 10.1002/pbc.28723
pubmed: 33037871
Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, Holmes EJ, Kun LE (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 68(6):1548–1555. https://doi.org/10.1227/NEU.0b013e318214a66e
doi: 10.1227/NEU.0b013e318214a66e
pubmed: 21368693
Yao R, Cheng A, Zhang Z, Jin B, Yu H (2023) Correlation between apparent diffusion coefficient and the Ki-67 proliferation index in grading pediatric glioma. J Comput Assist Tomogr 47(2):322–328. https://doi.org/10.1097/RCT.0000000000001400
doi: 10.1097/RCT.0000000000001400
pubmed: 36957971
pmcid: 10045956